Altropane, a SPECT or PET imaging probe for dopamine neurons: I. Dopamine transporter binding in primate brain

Synapse

Volumn 29, Issue 2, 1998, Pages 93-104

  Madras, Bertha K ^a   Meltzer, Peter C ^b   Liang, Anna Y ^b   Elmaleh, David R ^c   Babich, John ^c   Fischman, Alan J ^c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b ORGANIX INC   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Aging; Cocaine; Dopamine neurons; Dopamine transporter; Parkinson's disease; PET imaging; SPECT imaging; WIN 35,428

Indexed keywords

3BETA (4 FLUOROPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; 3BETA (4 IODOPHENYL) 2BETA TROPANECARBOXYLIC ACID ISOPROPYL ESTER; 3BETA (4 IODOPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; ALTROPANE; BROMALTROPANE; CITALOPRAM; COCAINE; DIFLUOROPINE; DOPAMINE; DOPAMINE TRANSPORTER; IODINE 125; MAZINDOL; SEROTONIN TRANSPORTER; TALSUPRAM; TRITIUM; TROPANE DERIVATIVE; UNCLASSIFIED DRUG; VANOXERINE;

ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BRAIN MEMBRANE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; DRUG STRUCTURE; FEMALE; MALE; MONKEY; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ANIMALS; BRAIN; BRAIN CHEMISTRY; CARRIER PROTEINS; CITALOPRAM; COCAINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; IODINE RADIOISOTOPES; LIGANDS; MACACA FASCICULARIS; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; NERVE TISSUE PROTEINS; PROTEIN BINDING; RECEPTORS, DOPAMINE D1; SEROTONIN UPTAKE INHIBITORS; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0031945368     PISSN: 08874476     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2396(199806)29:2<93::AID-SYN1>3.0.CO;2-5     Document Type: Article

References (73)

1. 3H]WIN 35,428 binding in rabbit caudate nucleus after repeated injections of cocaine. Pharmacol. Biochem. Behav., 52:335-340.
2. Bergman, J., Madras, B.K., Johnson, S.E., and Spealman, R.D. (1989) Effects of cocaine and related drugs in nonhuman primates. III. Self-administration by squirrel monkeys. J Pharmacol. Exp. Ther., 251:150-155.
3. 125I]RTI-SS to dopamine and serotonin transporters in rat brain. Synapse, 12:27-36.
4. 125I]iodophenyl)tropane-2β-carboxylic acid isopropyl ester. Mol. Pharmacol., 47:779-786.
5. Brownell, A.-L., Elmaleh, D.R., Meltzer, P.C., Shoup, T.M., Brownell, G.L., Fischman, A.J., and Madras, B.K. (1996) Cocaine congeners as PET imaging probes for dopamine terminals. J. Nucl. Med., 37:1186-1192.
6. 3H]WIN 35,428) in the monkey brain. Synapse, 6:189-195.
7. Carroll, F.I., Gao, Y, Rahman, M.A., Abraham, P., Parham, K., Lewin, A.H., Boja, J.W., and Kuhar, M.J. (1991) Synthesis, ligand binding, QSAR, and CoMFA study of 3β-(p-substituted phenyl)tropane-2B-carboxylic acid methyl esters. J. Med. Chem., 34:2719-2725.
8. Carroll, F.I., Gao, Y., Abraham, P., Lewin, A.H., Parham, K.A., Boja, J.W., and Kuhar, M.J. (1992) Isopropyl and phenylesters of 3β-(4-substituted phenyl) tropane-2β-carboxylic acids. Potent and selective compounds for the dopamine transporter. J. Med. Chem., 35:2497-2500.
9. Ciliax, B.J., Heilman, C., Demchyshyn, L.L., Pristupa, Z.B., Ince, E., Hersch, S.M., Niznik, H.B., and Levey, A.I. (1994) The dopamine transporter: Immunochemical characterization and localization in brain. J. Neurosci., 15:1714-1723.
10. Clarke, R.L., Daum, S.J., Gambino, A.J., Aceto, M.D., Pearl, J., Levitt, M., Cumiskey, W.R., and Bogado, E.F. (1973) Compounds affecting the central nervous system. 4. 3β-phenyltropane-2-carboxylic esters and analogs. J. Med. Chem., 16:1260-1267.
11. Elmaleh, D.R., Fischman, A.J., Shoup, T.M., Byon, C., Hanson, R.N., Liang, A.Y., Meltzer, P.C., and Madras, B.K. (1996) Preparation and biological evaluation of iodine-125-IACFT: A selective SPECT agent for imaging dopamine transporter sites. J. Nucl. Med., 37:1197-1202.
12. Elsworth, J.D., Al-Tikriti, M.S., Sladek, J.R., Jr., Taylor, J.R., Innis, R.B., Redmond, D.E., Jr., and Roth, R.H. (1994) Novel radioligands for the dopamine transporter demonstrate the presence of intrastriatal nigral grafts in the MPTP-treated monkey: Correlation with improved behavioral function. Exp. Neurol., 126:300-304.
13. Emond, P., Garreau, L., Chalon, S., Boazi, M., Caillet, M., Bricard, J., Frangin, Y., Mauclaire, L., Besnard, J.-C., and Guilloteau, D. (1997) Synthesis and ligand binding of nortropane derivatives: N-substituted 2β-carbomethoxy-3β-(4'-iodophenyl)nortropane and N-(3-iodoprop-(2E)-enyl)-2β-carbomethoxy-3β-(3',4'-disubstituted phenyl)nortropane. New high-affinity and selective compounds for the dopamine transporter. J. Med. Chem., 40:1366-1372.
14. 11C]β-CIT binding to monoamine transporters in the monkey and human brain.
15. 123I]IACFT): Initial experience in humans. Neuroscience-Net, 1: Article #10010, HTTP://www.neuroscience.com.
16. Fischman, A.J., Babich, J.W., Elmaleh, D.R., Barrow, S.A., Meltzer, P.C., and Madras, B.K. (1997a) SPECT imaging of dopamine transporter sites in normal and MPTP treated rhesus monkeys. J. Nucl. Med., 38:144-150.
17. Fischman, A.J., Bonab, A.A., Babich, J.W., Palmer, P., Alpert, N.M., Elmaleh, D.R., Barrow, S.A., Graham, W., Meltzer, P.C., Hanson, R.H., and Madras, B.K. (1998) Rapid detection of Parkinson's disease by SPECT with Altropane: A selective ligand for dopamine transporters. Synapse, 29:128-141.
18. 11C-WIN 35,428 reveals marked declines in mild Parkinson's disease. Ann. Neurol., 34:423-431.
19. Garreau, L., Emond, P., Belzung, C., Guilloteau, D., Frangin, Y., Besnard, J.-C., and Chalon, S. (1997) N-(3-iodoprop-2E-enyl)-2β-carbomethoxy-3β-(3',4'-dichlorophenyl) nortropane (β-CDIT), a tropane derivative: Pharmacological characterization as a specific ligand for the dopamine transporter in the rodent brain. J. Pharmacol. Exp. Ther., 282:467-474.
20. Gaspar, P.A., Febvret, A., and Colombo, J. (1993). Serotonergic sprouting in primate MPTP-induced hemiparkinsonism. Exp. Brain Res., 96:100-106.
21. Goodman, M.M., Kung, M.-P., Kabalka, G.W., Kung, H.F., and Switzer, R. (1994) Synthesis and characterization of radioiodinated N-(3-Iodopropen-1-yl)-2β-carbomethoxy-3β-(4-chlorophenyl)tropanes: Potential dopamine reuptake site imaging agents. J. Med. Chem., 37:1535-1542.
22. Goodman, M.M., Keil, R., Shoup, T.M., Eshima, D., Eshima, L., Kilts, CI, Votaw, J., Camp, V.M., Votaw, D., Smith, E., Kung, M.-P., Malveaux, E., Watts, R., Huerkamp, M., Wu, D., Garcia, E., and Hoffman, J.M. (1997) Fluorine-18-FPCT: A PET radiotracer for imaging dopamine transporters. J. Nucl. Med., 38:119-126.
23. Halldin, C., Farde, L., Lundkvist, C., Ginovart, N., Nakashima, Y., Karlsson, P., and Swahn, C.G. (1996) [11C]beta-CIT-FE, a radioligand for quantification of the dopamine transporter in the living brain using positron emission tomography. Synapse, 22:396-390.
24. 123I]CIT. Eur. J. Pharm., 200:369-370.
25. 3H]GBR-12935 binding to the dopamine transporter is decreased in the caudate nucleus in Parkinson's disease. J. Neurochem., 49:617-621.
26. Kaufman, M.J., and Madras, B.K. (1991) Severe depletion of cocaine recognition sites associated with the dopamine transporter in Parkinson's diseased striatum. Synapse, 9:43-49.
27. 125I]RTI-55. Synapse, 12:99-111.
28. 3H]CFT. Synapse, 9:177-187.
29. 3H]WIN 35,428) accumulation in dopamine regions of monkey brain: Comparison of a mature and an aged monkey. Brain Res., 611:322-325.
30. Kennedy, L.T., and Hanbauer, I. (1983) Sodium-sensitive cocaine binding to rat striatal membrane: Possible relationship to dopamine uptake sites. J. Neurochem., 41:172-178.
31. Kish, S.J., Shannak, K., and Hornykiewicz, O. (1988) Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. N. Engl. J. Med., 318:876-880.
32. Kuhar, M.J., Sanchez-Roa, P.M., Wong, D.F., Dannals, D.F., Grigoriadis, D.E., Lew, R., and Milberger, M. (1990) Dopamine transporter: Biochemistry, pharmacology and imaging. Eur. Neurol., 30:15-20.
33. 3H]WIN 35,428 binding sites in human striatum. Brain Res., 628:17-25.
34. 3H]Cocaine binding sites in caudate-putamen. J. Pharmacol. Exp. Ther., 251:131-141.
35. 3H]2β-carbomethoxy-3β-(4-fluorophenyl)tropane. Mol. Pharmacol., 36:518-524.
36. 3H]Lu 19-005: Markers for cocaine receptors/dopamine nerve terminals in Parkinson's disease. Soc. Neurosci. Abst., 16:14.
37. 3H]cocaine receptors. Pharmacol. Biochem. Behav., 35:949-953.
38. Madras, B.K., Fahey, M.A., Kaufman, M.J., Spealman, R.D., Schumacher, J., Isacson, O., Brownell, A.-L., Brownell, G., and Elmaleh, D.R. (1991) Cocaine receptor probes in nonhuman and human brain: In vitro characterization and in vivo imaging. Soc. Neurosci. Abst., 17:190.
39. Madras, B.K., Elmaleh, D.R., Meltzer, P.C., and Brownell, A.-L. (1994) Positron emission tomography of the dopamine transporter. NIDA Res. Monograph, 138. In: Imaging Techniques in Medications Development: Preclinical and Clinical Aspects. H. Sorer and R.S. Rapaka, eds., pp. 57-69.
40. Madras, B.K., Gracz, L.M., Kaufman, M.J., Meltzer, P.C., Elmaleh, D.R., and Fischman, A.J. (1995) A novel SPECT imaging agent detects total loss of the dopamine transporter in parkinsonian monkeys. Soc. Neurosci. Abst., 21:1983.
41. 99mtechnetium probe to label the dopamine transporter in brain by SPECT imaging. Synapse, 22:239-246.
42. Madras, B.K., Pristupa, Z.B., Niznik, H.B., Liang, A.Y., Blundell, P., Gonzalez, M.D., and Meltzer, P.C. (1996b) Nitrogen-based drugs are not essential for blockade of monoamine transporters. Synapse, 24:340-348.
43. Madras, B.K., Gracz, L.M., Meltzer, P.C., Liang, A.Y., Elmaleh, D.R., and Fischman, A.J. (1998a) Altropane, a SPECT or PET imaging probe for dopamine neurons. II. Distribution to dopamine-rich regions of primate brain. Synapse 29:105-115.
44. Madras, B.K., Gracz, L.M., Meltzer, P.C., Babich, J., and Fischman, A.J. (1998b) Altropane, a SPECT or PET imaging probe for dopamine neurons. III. Human dopamine transporter in postmortem normal and Parkinson's diseased brain. Synapse 29:116-127.
45. 123I]β-CIT SPECT imaging of striatal dopamine transporter binding in Tourette's disorder. Am. J. Psychiatry, 152:1359-1361.
46. Mash, D.C., Staley, J.K., Doepel, F.M., Young, S.N., Ervin, F.R., and Palmour, R.M. (1996) Altered dopamine transporter densities in alcohol-preferring vervet monkeys. Neuroreport, 7:457-462.
47. Meegalla, S.K., Plossl, K., Kung, M.-P., Chumpradit, S., Stevenson, D.A., Kushner, S.A., McElgin, W.T., Mozley, P.D., and Kung, H.F. (1997). Synthesis and characterization of technetium-99m-labeled tropanes as dopamine transporter-imaging agents. J. Med. Chem., 40:9-17.
48. Meltzer, P.C., Liang, A.Y., Brownell, A.-L., Elmaleh, D.R., and Madras, B.K. (1993) Substituted 3-phenyltropane analogs of cocaine: Synthesis, inhibition of binding at cocaine recognition sites, and positron emission tomography imaging. J. Med. Chem., 36:855-862.
49. Meltzer, P.C., Liang, A.Y., and Madras, B.K. (1994) The discovery of an unusually selective and novel cocaine analog: Difluoropine. Synthesis and inhibition of binding at cocaine recognition sites. J. Med. Chem., 37:2001-2010.
50. Meltzer, P.C., Liang, A.Y., and Madras, B.K. (1996) 2-carbomethoxy-3-(diarylmethoxy)-1 alpha H, 5 alpha H-tropane analogs: Synthesis and inhibition of binding at the dopamine transporter and comparison with piperazines of the GBR series. J. Med. Chem., 39:371-379.
51. 99mSPECT imaging agent which targets the dopamine transporter in primate brain. J. Med. Chem., 40:1835-1844.
52. 11C-CFT. Synapse, 24:262-272.
53. Neumeyer, J.L., Wang, S., Gao, Y., Milius, R.A., Kula, N.S., Campbell, A., Baldessarini, R.J., Zea-Ponce, Y., Baldwin, R.M., and Innis, R.B. (1994) N-ω-fluoroalkyl analogs of (1R)-2β-carbomethoxy-3β-(4-iodophenyl)-tropane (β-CIT): Radiotracers for positron emission tomography and single photon emission computed tomography imaging of dopamine transporters. J. Med. Chem., 37:1558-1561.
54. Nirenberg, M.J., Chan, J., Vaughn, R.A., Uhl, G.R., Kuhar, M.J., and Pickel, V.M. (1997) Immunogold localization of the dopamine transporter: An ultrastructural study of the rat ventral tegmental area. J. Neurosci., 17:5255-5262.
55. Pilotte, N.S., Sharpe, L.G., Rountree, S.D., and Kuhar, M.J. (1996) Cocaine withdrawal reduces dopamine transporter binding in the shell of the nucleus accumbens. Synapse, 22:87-92.
56. Reith, M.E., Meisler, B.E., Sershen, H., and Lajtha, A. (1986) Structural requirements for cocaine congeners to interact with dopamine and serotonin uptake sites in mouse brain and to induce stereotyped behavior. Biochem. Pharmacol., 35:1123-1129.
57. Ritz, M.C., Lamb, R.J., Goldberg, S.R., and Kuhar, M.J. (1987) Cocaine receptors on dopamine transporters are related to self-administration of cocaine. Science, 237:1219-1223.
58. 3H]cocaine binding associated with dopamine uptake sites in the rat striatum and human putamen decrease after dopaminergic denervation and in Parkinson's disease. Naunyn Schmiedebergs Arch. Pharmacol., 329:227-235.
59. 123I]β-CIT striatal uptake correlates with symptom severity in Parkinson's disease. Ann. Neurol., 38:589-598.
60. Singer, H.S., Hahn, I.-H., and Moran, T.H. (1991) Abnormal dopamine uptake sites in postmortem striatum from patients with Tourette's syndrome. Ann. Neurol., 30:558-562.
61. Spealman, R.D., Madras, B.K., and Bergman, J. (1989) Effects of cocaine and related drugs in nonhuman primates. II. Stimulant effects on schedule-controlled behavior. J. Pharmacol. Exp. Ther., 251:142-149.
62. Staley, J.K., Hearn, W.L., Ruttenber, A.J., Wetli, C.V., and Mash, D.C. (1994) High affinity cocaine recognition sites on the dopamine transporter are elevated in fatal cocaine overdose victims. J. Pharmacol. Exp. Ther., 271:1678-1685.
63. Staley, J.K., Boja, J.W., Carroll, I.V., Seltzman, H.H., Wyrick, C.D., Lewin, A.H., and Abraham, P. (1995) Mapping dopamine transporters in human brain with novel selective cocaine analog [125I]RTI-121. Synapse, 21:364-372.
64. Takeuchi, Y., Sawada, T., Blunt, S., Jenner, P., Marsden, C.D. (1991) Serotonerigc sprouting in the neostriatum after intrastriatal transplantation of fetal ventral mesencephalon. Brain Res., 551:171-177.
65. Tiihonen, J., Kuikka, J., Bergstrom, K., Hakola, P., Karhu, J., Ryynanen, O.P., and Fohr, J. (1995) Altered striatal dopamine re-uptake site densities in habitually violent and non-violent alcoholics. Nat. Med., 1:654-657.
66. van Dyck, C.H., Seibyl, J.P., Malison, R.T., Laruelle, M., Wallace, E., Zoghbi, S.S., Zea-Ponce, Y., Baldwin, R.M., Charney, D.S., Hoffer, P.B., and Innis, R.B. (1995) Age-related decline in striatal dopamine transporter binding with iodine-123-β-CIT SPECT. J. Nucl. Med., 36:1175-1181.
67. Vaughan, R.A., Brown, V.L., McCoy, M.T., and Kuhar, M.J. (1996) Species- and brain region-specific dopamine transporters: Immunological and glycosylation characteristics. J. Neurochem., 66:2146-2152.
68. Volkow, N.D., Fowler, J.S., Logan, J., Gatley, S.J., Dewey, S.L., MacGregor, R.R., Schlyer, D.J., Pappas, N., King, P., Wang, G.-J., and Wolf, A.P. (1995a) Carbon-11-cocaine binding compared at subpharmacological and pharmacological doses: A PET study. J. Nucl. Med., 36:1289-1297.
69. Volkow, N.D., Gatley, S.J., Fowler, J.S., Chen, R., Logan, J., Dewey, S.L., Ding, Y.-S., Pappas, N., King, P., MacGregor, R.R., Kuhar, M.J., Carroll, F.I., and Wolf, A.P. (1995b) Long-lasting inhibition of in vivo cocaine binding to dopamine transporters by 3β-(4-iodophenyl)tropane-2-carboxylic acid methyl ester:RTI-55 or β-CIT. Synapse, 19:206-211.
70. Volkow, N.D., Wang, G.J., Fischman, M.W., Foitin, R.W., Fowler, J.S., Abumrad, N.N., Vitkun, S., Logan, J., Gatley, S.J., Pappas, N., Hitzeman, R., and Shea, C.E. (1997) Relationship between subjective effects of cocaine and dopamine transporter occupancy. Nature, 386:827-830.
71. 11C]WIN 35,428. Synapse, 15:130-142.
72. ong, D.F., Harris, J.C., Naidu, S., Yokoi, F., Marenco, S., Dannals, R.F., Ravert, H.T., Yaster, M., Evans, A., Rousset, O., Bryan, R.N., Gjedde, A., Kuhar, M.J., and Breese, G.R. (1996) Dopamine transporters are markedly reduced in Lesch-Nyhan disease in vivo. Proc. Natl. Acad. Sci. U.S.A., 93:5539-5543.
73. Zelnik, N., Angel, I., Paul, S.M., and Kleinman, J.E. (1986) Decreased density of human striatal dopamine uptake sites with age. Eur. J. Pharmacol., 126:175-176.